Clinical Trials on Chronic Idiopathic Constipation (CIC) in Austria

Total 38 results

SK Life Science, Inc.

Completed

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Braintree Laboratories

Completed

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Chronic Idiopathic Constipation

United States
Bausch Health Americas, Inc.

Completed

12-Week Study of Plecanatide for CIC (The National CIC3 Study) (CIC)

Chronic Idiopathic Constipation

United States
Bausch Health Americas, Inc.

Completed

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Chronic Idiopathic Constipation

United States, Canada
Bausch Health Americas, Inc.
Syneos Health

Completed

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation

United States, Canada
Norgine

Completed

An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children

Chronic Constipation

Australia
AstraZeneca

Completed

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States, Australia, Slovakia, Germany
AstraZeneca

Completed

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States, Germany, Australia, Slovakia
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Alkermes, Inc.

Completed

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

OIC

United States
Ironwood Pharmaceuticals, Inc.

Completed

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Chronic Constipation

United States
AstraZeneca

Completed

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
AstraZeneca

Completed

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

Croatia, Sweden, United States, Czech Republic, Spain, Hungary, United Kingdom, Belgium
Genentech, Inc.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Chronic Refractory Cough (CRC) With Non-atopic Asthma | CRC With Atopic Asthma | Unexplained Chronic Cough | CRC With Chronic Obstructive Pulmonary Disease | CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

United States, Australia, United Kingdom, Canada
Bayside Health

Unknown

The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema

Angioedema | Urticaria

Australia
St Vincent's Hospital Melbourne

Completed

The Multi-disciplinary Treatment of Functional Gut Disorders Study (MANTRA)

Functional Dyspepsia | Irritable Bowel Syndrome | Constipation - Functional | Faecal Incontinence | Functional Abdominal Pain Syndrome | Other Rome IV Functional Gastrointestinal Disorders

Australia
Zai Lab Pty. Ltd.

Unknown

Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease | Asthma | Idiopathic Pulmonary Fibrosis

Australia
Shionogi

Completed

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Opioid-induced Constipation

United States
Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Bausch Health Americas, Inc.

Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Klinikum Floridsdorf
Medical University of Vienna; Klinik Favoriten; Salzkammergut Klinikum Vöcklabruck

Completed

BMI and Lymph Node Count in Colorectal Cancer

The Aim of This Study is to Determine the Influence of BMI and Lymph Node Status on OS in CRC Patients in the Long Term

Austria
Genentech, Inc.

Completed

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Chronic Idiopathic Urticaria

Germany, United Kingdom, United States, Switzerland, Australia, New Zealand, Poland, Singapore
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 1)

Non-Constipation Irritable Bowel Syndrome

United States, Canada
Neovii Biotech

Completed

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Bronchiectasis | Idiopathic Pulmonary Fibrosis | Cystic Fibrosis | Chronic Obstructive Pulmonary | Pulmonary Vascular Disease

United States, Australia, Austria, Canada
Zambon SpA

Completed

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Idiopathic Parkinson Disease

Spain, Austria, Italy, Germany, France
Eisai Inc.

Completed

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Immune Thrombocytopenia | Chronic Thrombocytopenia

Poland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia
Incyte Corporation

Terminated

Study of Ruxolitinib in Colorectal Cancer Patients

CRC (Colorectal Cancer)

United States, France, United Kingdom, Spain, Israel, Australia, Germany, Korea, Democratic People's Republic of
Amgen

Active, not recruiting

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300)

Colorectal Cancer (CRC)

France, Spain, Korea, Republic of, United States, United Kingdom, Taiwan, Italy, Greece, Australia, Japan, Germany, Mexico
Revolution Medicines, Inc.

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Revolution Medicines, Inc.

Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa

Clinical Trials on Chronic Idiopathic Constipation (CIC) in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations